We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
On October 12, CDE official website showed that the import application submitted by SciClone Pharmaceuticals for type 5.1 telavancin hydrochloride for injection was accepted.